Psychedelic microdosing benefits and challenges: an empirical codebook

Microdosing refers to taking sub-hallucinogenic amounts of classic psychedelics such as LSD or psilocybin. Public interest in the practice has grown rapidly, with large online communities reporting subjective benefits, yet scientific investigation remains limited and largely exploratory. The authors note that outcomes observed in full-dose psychedelic research (for example, effects on depression, addiction, personality and mystical-type experiences) may not fully predict microdosing effects because microdoses are intended to avoid overt perceptual alteration; thus unanticipated, dose-specific benefits and challenges could occur. This study aims to generate a data-driven taxonomy of microdosing benefits and challenges (the MDBC taxonomy) by analysing open-ended reports from a community sample of recreational microdosers. Using an exploratory, grounded-theory approach, Anderson and colleagues seek to catalogue commonly reported outcomes and to highlight candidate targets for future experimental research, including whether outcomes vary by substance (LSD-only, psilocybin-only, or both).

The researchers conducted a cross-sectional, retrospective, anonymous online survey targeting people with self-reported microdosing experience. Recruitment occurred primarily via Reddit subreddits related to microdosing and psychedelic topics. The analytic sample for the present paper comprised 278 respondents who reported microdosing with LSD-only (N = 195), psilocybin-only (N = 50), or both LSD and psilocybin (N = 33); respondents who used other substances for microdosing were excluded from this analysis. Participants provided up to three open-ended benefits and up to three open-ended challenges associated with their microdosing, each as short text responses, and rated the subjective importance of each reported outcome on a 0–100 sliding scale. After these open-ended items, respondents also answered targeted, structured questions about changes in health behaviours (mood, anxiety, meditation practice, exercise, eating, sleep) and reductions in use of specific substances (caffeine, alcohol, cannabis, tobacco, psychiatric prescriptions, illicit drugs). For qualitative analysis the study team used classic grounded theory methods. Two coding authors independently coded all open-ended responses, iteratively discussed discrepancies until saturation, and built a three-tier hierarchy (codes, sub-categories, categories) over five refinement passes. Inter-rater agreement exceeded 85% at every hierarchical level for both benefits and challenges. Each response was double-coded and frequencies were adjusted by halving the summed codes, which can yield non-integer category counts. Statistical comparisons between substance groups used non-parametric tests where appropriate: Wilcoxon signed-rank tests for non-normally distributed importance ratings and chi-square tests to compare reporting rates across groups.

Grounded-theory coding produced 807.5 coded benefit items, organised into 46 codes, 21 sub-categories, and 11 higher-level benefit categories. The single most frequent low-level codes were improved mood (12.8% of coded benefits), improved focus (10.0%), creativity (9.4%), and improved energy (7.6%). At the category level, the largest benefit categories were improved mood (26.6%, 215 reports), improved focus (14.8%, 119.5 reports), creativity (12.9%, 104 reports), self-efficacy (11.3%, 91.5 reports), and improved energy (10.5%, 84.5 reports). Smaller categories included social benefits, cognitive benefits, reduced anxiety, physiological enhancement, and miscellaneous items. For challenges, coding yielded 603.5 items organised into 44 codes, 23 sub-categories, and 11 challenge categories. The most frequent low-level challenge codes were illegality (10.8%), dose accuracy (9.1%), poor focus (8.8%), and anxiety (5.3%). At the category level, illegality was the most commonly reported challenge (29.5%, 178 reports), followed by physiological discomfort (18.0%, 108.5 reports), impaired focus (8.8%, 53 reports), impaired energy (7.2%, 43.5 reports), increased anxiety (6.7%, 40.5 reports), and impaired mood (6.9%, 41.5 reports). Other categories captured social, cognitive, and self-related interference as well as miscellaneous concerns. When comparing substances, psilocybin-only microdosers rated their reported benefits as subjectively more important than LSD-only microdosers (Wilcoxon W = 3658, p < 0.01, effect size d = 0.353; psilocybin median = 87.83, SD = 15.76; LSD median = 76.67, SD = 14.59). There were no significant differences between groups for the subjective importance of challenges (W = 3841.5, p = 0.56, d = 0.079). Rates at which specific benefit or challenge categories were reported did not differ significantly across the three substance groups (benefits χ2(20) = 17.26, p = 0.636; challenges χ2(20) = 7.73, p = 0.994). In the targeted, structured items following the open-ended questions, large proportions of respondents reported perceived improvements: mood (92.9%), anxiety (59.2%), meditative practice (49.1%), exercise (49.1%), eating habits (36.0%), and sleep (28.8%). Many respondents also reported reductions in substance use: caffeine (44.2%), alcohol (42.3%), cannabis (30.3%), tobacco (21.0%), psychiatric prescription medications (16.9%), and illicit substances (16.1%).

Using reports from an active online microdosing community, Anderson and colleagues constructed an initial empirical taxonomy of perceived benefits and challenges associated with psychedelic microdosing. The taxonomy identifies mood, focus, creativity and self-efficacy as commonly reported benefits, and highlights illegality and physiological discomfort as prominent challenges; the authors suggest these constructs as priority targets for future experimental investigation. They caution that the present findings are inherently descriptive and cannot establish causation. A notable emergent pattern was ‘‘parallelism’’ — many outcome categories appeared on both the benefit and challenge lists (for example, focus, mood and energy), suggesting two non-exclusive explanations proposed by the authors: (1) expectancy and placebo effects could drive heterogeneous reports, producing mirror-image outcomes across individuals; and (2) real individual differences (genetic, psychopathological, personality, or metabolic) may moderate directional responses to microdosing. The paper discusses plausible biological moderators, for instance variation in HTR2A receptor genetics and their potential impact on response, and notes that context and cognitive interpretation of physiological changes might also shape whether an effect is experienced as beneficial or detrimental. The authors emphasise unique findings that may be particularly fruitful to study further. Creativity emerged as a benefit without a clear parallel challenge, aligning with prior reports and suggesting targeted assessment of divergent and convergent creative processes. Illegality ranked as the most common challenge, but this is a socio-legal barrier rather than a pharmacological adverse effect; it encompasses purity, dose-accuracy, supply, cost and stigma. The targeted behavioural items showing high rates of self-reported mood improvement and reduced use of substances such as alcohol, tobacco and caffeine are highlighted as hypotheses suitable for placebo-controlled trials. Limitations recognised by the authors include the observational, retrospective design without experimental manipulation or dose control, potential recall and expectancy/placebo biases, and the inability to verify substance purity or dosing. Sampling was non-random and skewed by recruitment via Reddit: respondents were relatively young (mean age 27.8), predominantly male and from Anglo-cultural countries, limiting generalisability. The qualitative coding process, though double-coded and transparent, is acknowledged as investigator-dependent; the authors therefore make coded and raw data available to support reanalysis. Ultimately they call for pre-registered, randomised, placebo-controlled trials and more representative sampling to test safety, efficacy and mechanisms, using the MDBC taxonomy to inform outcome selection and measurement.

Anderson and colleagues present an initial, empirically grounded taxonomy of perceived benefits and challenges of psychedelic microdosing derived from open-ended reports by 278 community microdosers. The MDBC taxonomy, together with the reported behavioural improvements and reductions in substance use, identifies candidate targets for focused experimental research. The authors conclude that randomised placebo-controlled trials are needed to test the safety and efficacy of microdosing and recommend that future work follow open-science principles; they also suggest that microdosing research could complement investigations of full-dose psychedelic therapies.